2 Information about sebelipase alfa

Marketing authorisation indication


Sebelipase alfa (Kanuma, Alexion) is indicated for 'long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency'.

Dosage in the marketing authorisation



The list price of sebelipase alfa is £6,286 for a 20 mg vial (excluding VAT; company submission).


The company has a commercial arrangement. This makes sebelipase alfa available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)